Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization

Che-Yi Chang,1,2,* Ming-Chen Wang,2,* Takuya Miyagawa,1 Zhi-Yu Chen,1 Feng-Huei Lin,3,4 Ko-Hua Chen,5,6 Guei-Sheung Liu,7 Ching-Li Tseng1 1Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 2Department of Biomedic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chang CY, Wang MC, Miyagawa T, Chen ZY, Lin FH, Chen KH, Liu GS, Tseng CL
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
RGD peptide
epigallocatechin gallate (EGCG)
hyaluronic acid (HA)
vascular endothelial cells
anti-angiogenesis
corneal neovascularization
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/d182185c1bd64859ac5390338a941c6b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d182185c1bd64859ac5390338a941c6b
record_format dspace
spelling oai:doaj.org-article:d182185c1bd64859ac5390338a941c6b2021-12-02T02:04:23ZPreparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization1178-2013https://doaj.org/article/d182185c1bd64859ac5390338a941c6b2016-12-01T00:00:00Zhttps://www.dovepress.com/preparation-of-argininendashglycinendashaspartic-acid-modified-biopoly-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Che-Yi Chang,1,2,* Ming-Chen Wang,2,* Takuya Miyagawa,1 Zhi-Yu Chen,1 Feng-Huei Lin,3,4 Ko-Hua Chen,5,6 Guei-Sheung Liu,7 Ching-Li Tseng1 1Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 2Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, 3Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan, 4Institute of Biomedical Engineering, National Taiwan University, 5Department of Ophthalmology, Taipei Veterans General Hospital, 6Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia *These authors contributed equally to this work Abstract: Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine–glycine–aspartic acid (RGD) peptide–hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the αvβ3 integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops. HA-RGD conjugation via COOH and amine groups was confirmed by 1H-nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The average diameter of GEH-RGD NPs was 168.87±22.5 nm with positive charge (19.7±2 mV), with an EGCG-loading efficiency up to 95%. Images of GEH-RGD NPs acquired from transmission electron microscopy showed a spherical shape and shell structure of about 200 nm. A slow-release pattern was observed in the nanoformulation at about 30% after 30 hours. Surface plasmon resonance confirmed that GEH-RGD NPs specifically bound to the integrin αvβ3. In vitro cell-viability assay showed that GEH-RGD efficiently inhibited HUVEC proliferation at low EGCG concentrations (20 µg/mL) when compared with EGCG or non-RGD-modified NPs. Furthermore, GEH-RGD NPs significantly inhibited HUVEC migration down to 58%, lasting for 24 hours. In the corneal NV mouse model, fewer and thinner vessels were observed in the alkali-burned cornea after treatment with GEH-RGD NP eyedrops. Overall, this study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity. Moreover, they can be used in eyedrops to inhibit angiogenesis in corneal NV mice. Keywords: RGD peptide, epigallocatechin gallate (EGCG), hyaluronic acid (HA), vascular endothelial cells, antiangiogenesis, corneal neovascularizationChang CYWang MCMiyagawa TChen ZYLin FHChen KHLiu GSTseng CLDove Medical PressarticleRGD peptideepigallocatechin gallate (EGCG)hyaluronic acid (HA)vascular endothelial cellsanti-angiogenesiscorneal neovascularizationMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 279-294 (2016)
institution DOAJ
collection DOAJ
language EN
topic RGD peptide
epigallocatechin gallate (EGCG)
hyaluronic acid (HA)
vascular endothelial cells
anti-angiogenesis
corneal neovascularization
Medicine (General)
R5-920
spellingShingle RGD peptide
epigallocatechin gallate (EGCG)
hyaluronic acid (HA)
vascular endothelial cells
anti-angiogenesis
corneal neovascularization
Medicine (General)
R5-920
Chang CY
Wang MC
Miyagawa T
Chen ZY
Lin FH
Chen KH
Liu GS
Tseng CL
Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
description Che-Yi Chang,1,2,* Ming-Chen Wang,2,* Takuya Miyagawa,1 Zhi-Yu Chen,1 Feng-Huei Lin,3,4 Ko-Hua Chen,5,6 Guei-Sheung Liu,7 Ching-Li Tseng1 1Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 2Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, 3Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan, 4Institute of Biomedical Engineering, National Taiwan University, 5Department of Ophthalmology, Taipei Veterans General Hospital, 6Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia *These authors contributed equally to this work Abstract: Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine–glycine–aspartic acid (RGD) peptide–hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the αvβ3 integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops. HA-RGD conjugation via COOH and amine groups was confirmed by 1H-nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The average diameter of GEH-RGD NPs was 168.87±22.5 nm with positive charge (19.7±2 mV), with an EGCG-loading efficiency up to 95%. Images of GEH-RGD NPs acquired from transmission electron microscopy showed a spherical shape and shell structure of about 200 nm. A slow-release pattern was observed in the nanoformulation at about 30% after 30 hours. Surface plasmon resonance confirmed that GEH-RGD NPs specifically bound to the integrin αvβ3. In vitro cell-viability assay showed that GEH-RGD efficiently inhibited HUVEC proliferation at low EGCG concentrations (20 µg/mL) when compared with EGCG or non-RGD-modified NPs. Furthermore, GEH-RGD NPs significantly inhibited HUVEC migration down to 58%, lasting for 24 hours. In the corneal NV mouse model, fewer and thinner vessels were observed in the alkali-burned cornea after treatment with GEH-RGD NP eyedrops. Overall, this study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity. Moreover, they can be used in eyedrops to inhibit angiogenesis in corneal NV mice. Keywords: RGD peptide, epigallocatechin gallate (EGCG), hyaluronic acid (HA), vascular endothelial cells, antiangiogenesis, corneal neovascularization
format article
author Chang CY
Wang MC
Miyagawa T
Chen ZY
Lin FH
Chen KH
Liu GS
Tseng CL
author_facet Chang CY
Wang MC
Miyagawa T
Chen ZY
Lin FH
Chen KH
Liu GS
Tseng CL
author_sort Chang CY
title Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
title_short Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
title_full Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
title_fullStr Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
title_full_unstemmed Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
title_sort preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/d182185c1bd64859ac5390338a941c6b
work_keys_str_mv AT changcy preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT wangmc preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT miyagawat preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT chenzy preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT linfh preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT chenkh preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT liugs preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
AT tsengcl preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization
_version_ 1718402737672028160

Ejemplares similares